HCC and Tumor Biomarkers: Does One Size Fits All?
Hepatocellular carcinoma (HCC) is a highly malignant disease and early diagnosis rates remain to be unsatisfactory. Owing to this limitation, advances in treatment options including liver transplantation (LT) are limited to improve survival. Recent HCC guidelines no longer recommend alpha-fetoprotei...
Saved in:
| Published in: | Journal of gastrointestinal cancer Vol. 51; no. 4; pp. 1122 - 1126 |
|---|---|
| Main Authors: | , |
| Format: | Journal Article |
| Language: | English |
| Published: |
New York
Springer US
01-12-2020
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Hepatocellular carcinoma (HCC) is a highly malignant disease and early diagnosis rates remain to be unsatisfactory. Owing to this limitation, advances in treatment options including liver transplantation (LT) are limited to improve survival. Recent HCC guidelines no longer recommend alpha-fetoprotein (AFP) as a surveillance and diagnostic tool for HCC. Hence, utilization of novel biomarkers has become imperative to improve disease management strategies. Noninvasive, serum-based biomarkers are potential options to aid early diagnosis as well as prompting treatment. However, further studies are required to find out the accuracy and potential of these approaches and introduce into clinical practice. |
|---|---|
| AbstractList | Hepatocellular carcinoma (HCC) is a highly malignant disease and early diagnosis rates remain to be unsatisfactory. Owing to this limitation, advances in treatment options including liver transplantation (LT) are limited to improve survival. Recent HCC guidelines no longer recommend alpha-fetoprotein (AFP) as a surveillance and diagnostic tool for HCC. Hence, utilization of novel biomarkers has become imperative to improve disease management strategies. Noninvasive, serum-based biomarkers are potential options to aid early diagnosis as well as prompting treatment. However, further studies are required to find out the accuracy and potential of these approaches and introduce into clinical practice. |
| Author | Otan, Emrah Ozgor, Dincer |
| Author_xml | – sequence: 1 givenname: Dincer surname: Ozgor fullname: Ozgor, Dincer email: drdincerozgor@gmail.com organization: Department of Surgery and Liver Transplant Institute, Inonu University Faculty of Medicine, Department of Surgery and Liver Transplant Institute, Inonu University Faculty of Medicine – sequence: 2 givenname: Emrah surname: Otan fullname: Otan, Emrah organization: Department of Surgery and Liver Transplant Institute, Inonu University Faculty of Medicine |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32827068$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kM1OwzAQhC1URH_gBTggH7kEdh3HcbggCJQiVeqBcraS2EEpaVLsRio8PYaUHjntandmpPnGZNC0jSHkHOEKAeJrhwxYEgCDAIDLKNgdkREmHAMhQjE47EwOydi5FYDgEeIJGYZMshiEHBGcpSnNGk2X3bq19L5q15l9N9bd0IfWOLpoDH2pvgydVltH7-r69pQcl1ntzNl-Tsjr9HGZzoL54uk5vZsHRcjjbYA5Ax4JLSFnLMQiR4YFxxx5HGmjpU40FFCyPBMm0v7MZCYTk3ONSRlLHk7IZZ-7se1HZ9xWrStXmLrOGtN2TjEeCg4gOfNS1ksL2zpnTak2tvI9PhWC-kGlelTKo1K_qNTOmy72-V2-Nvpg-WPjBWEvcP7VvBmrVm1nG9_5v9hvP0JzUw |
| CitedBy_id | crossref_primary_10_3389_fcell_2021_762588 crossref_primary_10_3390_microorganisms8101575 crossref_primary_10_1186_s43141_021_00262_8 crossref_primary_10_4251_wjgo_v14_i6_1067 |
| Cites_doi | 10.1371/journal.pone.0173897 10.2147/OTT.S186230 10.1016/j.bbagen.2005.03.012 10.1016/j.jhep.2018.03.019 10.1186/s12943-019-1085-0 10.3390/biology9040075 10.1002/prca.200900151 10.18632/oncotarget.10781 10.4254/wjh.v11.i1.50 10.1007/s11517-018-1811-6 10.1186/s12964-018-0315-1 10.1007/s10719-018-9838-3 10.3748/wjg.v12.i8.1175 10.1371/journal.pone.0151069 10.1016/j.bpg.2014.07.018 10.1002/mgg3.1012 10.1007/s12029-017-9965-2 10.18632/oncotarget.25074 10.3389/fonc.2017.00328 10.1159/000367735 10.3349/ymj.2015.56.5.1296 10.4103/0973-1482.199784 10.2147/OTT.S229835 10.1038/s41598-019-48043-1 10.1136/gutjnl-2017-315193 10.1007/s13277-015-4074-y 10.3748/wjg.v22.i1.262 10.3390/jcm9051541 10.1186/s13046-018-0893-1 10.1158/0008-5472.CAN-15-3199 10.4251/wjgo.v11.i10.887 10.1038/s41598-019-47365-4 10.1016/j.celrep.2018.10.091 10.1038/s41419-018-0534-9 10.1186/s12967-018-1546-z 10.2147/OTT.S163266 10.1002/lt.25062 |
| ContentType | Journal Article |
| Copyright | Springer Science+Business Media, LLC, part of Springer Nature 2020 |
| Copyright_xml | – notice: Springer Science+Business Media, LLC, part of Springer Nature 2020 |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
| DOI | 10.1007/s12029-020-00485-x |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE |
| Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1941-6636 |
| EndPage | 1126 |
| ExternalDocumentID | 10_1007_s12029_020_00485_x 32827068 |
| Genre | Journal Article Review |
| GroupedDBID | --- -5E -5G -BR -EM -Y2 -~C .VR 06C 06D 0R~ 0VY 1N0 203 29K 29~ 2J2 2JN 2JY 2KG 2LR 2VQ 2~H 30V 4.4 406 408 40D 40E 53G 5GY 5VS 6NX 8TC 95- 95. 95~ 96X AAAVM AABHQ AABYN AAFGU AAHNG AAIAL AAJKR AAKSU AANXM AANZL AARHV AARTL AATNV AATVU AAUYE AAWCG AAYFA AAYIU AAYQN AAYTO ABDZT ABECU ABFGW ABFTV ABHLI ABHQN ABJNI ABJOX ABKAS ABKCH ABMNI ABMQK ABNWP ABPLI ABQBU ABSXP ABTEG ABTKH ABTMW ABWNU ABXPI ACBMV ACBRV ACBYP ACCUX ACGFS ACHSB ACHVE ACHXU ACIGE ACIPQ ACKNC ACMDZ ACMLO ACOKC ACOMO ACSNA ACTTH ACUDM ACVWB ACWMK ADHIR ADINQ ADKNI ADKPE ADMDM ADOXG ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEEQQ AEFTE AEGAL AEGNC AEJHL AEJRE AEKMD AEOHA AEPYU AESKC AESTI AETLH AEVLU AEVTX AEXYK AFAFS AFEXP AFLOW AFNRJ AFQWF AFWTZ AFZKB AGAYW AGDGC AGGBP AGJBK AGKHE AGMZJ AGQMX AGWIL AGWZB AGYKE AHAVH AHBYD AHSBF AIAKS AIIXL AILAN AIMYW AITGF AJBLW AJDOV AJRNO AJZVZ AKMHD AKQUC ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BDATZ BGNMA CAG COF CS3 CSCUP D-I DDRTE DNIVK DPUIP EBLON EBS EIOEI EJD ESBYG F5P FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GRRUI HF~ HG6 HMJXF HRMNR HZ~ IJ- IKXTQ IWAJR IXD I~X I~Z J-C J0Z JBSCW JZLTJ KOV LLZTM M4Y MA- N2Q N9A NPVJJ NQJWS NU0 O9- O9J OVD P9S PF0 PT4 QOK QOR R89 R9I ROL RSV S16 S1Z S27 S37 S3B SAP SCLPG SDE SHX SISQX SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SZ9 SZN T13 TEORI TSG TT1 TUC U2A U9L UG4 UNUBA UOJIU UTJUX UZXMN VC2 VFIZW W48 WK8 YLTOR Z7U Z7W Z82 Z87 ZMTXR ZOVNA ~A9 ~KM AACDK AAEOY AAJBT AASML AAYZH ABAKF ACAOD ACDTI ACZOJ AEFQL AEMSY AFBBN AGQEE AGRTI AIGIU AJOOF CGR CUY CVF ECM EIF H13 NPM SJYHP AAYXX CITATION 7X8 |
| ID | FETCH-LOGICAL-c347t-1b20456d80b2231cb121c41b1475ded8d9d0c0f2ba6e5db1428a89eb4d19f7843 |
| IEDL.DBID | AEJHL |
| ISSN | 1941-6628 |
| IngestDate | Fri Oct 25 10:50:02 EDT 2024 Thu Nov 21 23:50:54 EST 2024 Wed Oct 16 00:43:21 EDT 2024 Sat Dec 16 12:03:21 EST 2023 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | Biomarkers Hepatocellular carcinoma Alpha-fetoprotein |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c347t-1b20456d80b2231cb121c41b1475ded8d9d0c0f2ba6e5db1428a89eb4d19f7843 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
| PMID | 32827068 |
| PQID | 2436400842 |
| PQPubID | 23479 |
| PageCount | 5 |
| ParticipantIDs | proquest_miscellaneous_2436400842 crossref_primary_10_1007_s12029_020_00485_x pubmed_primary_32827068 springer_journals_10_1007_s12029_020_00485_x |
| PublicationCentury | 2000 |
| PublicationDate | 2020-12-01 |
| PublicationDateYYYYMMDD | 2020-12-01 |
| PublicationDate_xml | – month: 12 year: 2020 text: 2020-12-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | New York |
| PublicationPlace_xml | – name: New York – name: United States |
| PublicationTitle | Journal of gastrointestinal cancer |
| PublicationTitleAbbrev | J Gastrointest Canc |
| PublicationTitleAlternate | J Gastrointest Cancer |
| PublicationYear | 2020 |
| Publisher | Springer US |
| Publisher_xml | – name: Springer US |
| References | HiroakiTTadashiNMitsuteruKAcylcarnitine: useful biomarker for early diagnosis of hepatocellular carcinoma in non-steatohepatitis patientsWorld J Gastrointest Oncol2019111088789710.4251/wjgo.v11.i10.887 ParkSJJangJYJeongSWUsefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinomaMedicine20179611 JiaoCCuiLPiaoJClinical significance and expression of serum Golgi protein 73 in primary hepatocellular carcinomaJ Can Res Ther201814123912441:CAS:528:DC%2BC1MXhvVWqs7rE JanfESJeongSHKimJWDiagnostic performance of alpha-fetoprotein, protein induced by vitamin K absence, osteopontin, Dickkopf-1 and its combinations for hepatocellular carcinomaPLoS One2016113e01510691:CAS:528:DC%2BC28Xht1WqtL3P10.1371/journal.pone.0151069 SunTLiPSunDPrognostic value of osteopontin in patients with hepatocellular carcinoma: a systematic review and meta-analysisMedicine20189743 KleinAMichalskiJCMorelleWModifications of human total serum N-glycome during liver fibrosis–cirrhosis, is it all about immunoglobulins?Proteomics Clin Appl201043723781:CAS:528:DC%2BC3cXktFyrurc%3D10.1002/prca.200900151 ZhangLChenJGaoCAn efficient model for auxiliary diagnosis of hepatocellular carcinoma based on gene expression programmingMed Biol Eng Comput2018561771177910.1007/s11517-018-1811-6 KayaalpCInceVErsanVKarakasSKahramanASYilmazSLiver transplantation for hepatocellular carcinoma at inonu universityJ Gastrointest Cancer20174826827110.1007/s12029-017-9965-2 OldenhoveGBoucqueyETauqinAPD-1 is involved in the dysregulation of type 2 innate lymphoid cells in a murine model of obesityCell Rep201825205320601:CAS:528:DC%2BC1cXitlShtbrI10.1016/j.celrep.2018.10.091 LinMLvDZhengYWuMXuCZhangQWuLDownregulation of cPT2 promotes tumorigenesis and chemoresistance to cisplatin in hepatocellular carcinomaOnco Targets Ther2018113101311010.2147/OTT.S163266 SeinoSTsuchiyaAWatanabeYKawataYKojimaYIkarashiSYanaiHNakamuraKKumakiDHiranoMFunakoshiKAonoTSakaiTSakataJTakamuraMKawaiHYamagiwaSWakaiTTeraiSClinical outcome of hepatocellular carcinoma can be predicted by the expression of hepatic progenitor cell markers and serum tumour markersOncotarget2018931218442186010.18632/oncotarget.25074 YoshidaYFurukawaJİNaitoSHigashinoKNumataYShinoharaYIdentification of unique glycoisoforms of vitamin D-binding protein and haptoglobin as biomarker candidates in hepatocarcinogenesis of STAM miceGlycoconj J2018354674761:CAS:528:DC%2BC1cXhs1ygtbnM10.1007/s10719-018-9838-3 HigaiKAokiYAzumaYMatsumotoKGlycosylation of site-specific glycans of α1-acid glycoprotein and alterations in acute and chronic inflammationBiochim Biophys Acta200517251281351:CAS:528:DC%2BD2MXos1aisro%3D10.1016/j.bbagen.2005.03.012 ÅstromEStålPZenlanderRReverse lectin ELISA for detecting fucosylated forms of α1- acid glycoprotein associated with hepatocellular carcinomaPLoS One2017123e017389710.1371/journal.pone.0173897 ChenLGuoPHeYHCC-derived exosomes elicit HCC progression and recurrence by epithelial- mesenchymal transition through MAPK/ ERK signalling pathwayCell Death Dis201895131:CAS:528:DC%2BC1cXhtVKnsrbJ10.1038/s41419-018-0534-9 FujiwaraNNakagawaHEnookuKKudoYHayataYNakatsukaTTanakaYTateishiRHikibaYMisumiKTanakaMHayashiAShibaharaJFukayamaMAritaJHasegawaKHirschfieldHHoshidaYHirataYOtsukaMTateishiKKoikeKCPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesityGut2018671121:CAS:528:DC%2BC1MXhvVKltL8%3D10.1136/gutjnl-2017-315193 CitoresMJLucenaJLde la FuenteSSerum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantationWorld J Hepatol2019111506410.4254/wjh.v11.i1.50 SunTTangYSunDBuQLiPOsteopontin versus alpha-fetoprotein as a diagnostic marker for hepatocellular carcinoma: a meta-analysisOnco Targets Therapy201811892589351:CAS:528:DC%2BC1MXitlKnt77N10.2147/OTT.S186230 de OliveiraRMOrnelas RicartCAAraujo MartinsAMUse of mass spectrometry to screen glycan early markers in hepatocellular carcinomaFront Oncol2018732810.3389/fonc.2017.00328 MocanTSimaoALCastroRELiquid biopsies in hepatocellular carcinoma: are we winning?J Clin Med.2020915411:CAS:528:DC%2BB3cXhtFWkurjE10.3390/jcm9051541 TangSKimPSA high-affinity human PD-1/PD-L2 complex informs avenues for small-molecule immune checkpoint drug discoveryPNAS20191164924506www.pnas.org/cgi/doi/10.1073/pnas.1916916116 LiXLiCZhangLWuMCaoKJiangFChenDLiNLiWThe significance of exosomes in the development and treatment of hepatocellular carcinomaMol Cancer202019110.1186/s12943-019-1085-0 Kagan, Zhu J, Wang M, et al. Evaluation of AGP fucosylation as a marker for hepatocellular carcinoma of three different etiologies. Sci Rep. 2019;9(1):11580. https://doi.org/10.1038/s41598-019-48043-1. Heo CK, Hwang HM, Lee HJ, et al. Serum anti-EIF3A autoantibody as a potential diagnostic marker for hepatocellular carcinoma. 2019;9:11059. https://doi.org/10.1038/s41598-019-47365-4www.nature.com/scientificreports. European Association for the Study of the LiverEASL clinical practice guidelines: management of hepatocellular carcinomaJ Hepatol20186918223610.1016/j.jhep.2018.03.019 ZhouLLiuJLuoFSerum tumor markers for detection of hepatocellular carcinomaWorld J Gastroenterol2006128117511811:CAS:528:DC%2BD28XjvFelu7s%3D10.3748/wjg.v12.i8.1175 SongPPXiaJFInagakiYHasegawaKSakamotoYKokudoNTangWControversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinomaWorld J Gastroenterol20162212622741:CAS:528:DC%2BC28XpsV2qtrY%3D10.3748/wjg.v22.i1.262 HwangHMHeoCKLeeHJKwakSSLimWHYooJSYuDYLimKJKimJYChoEWIdentification of anti-SF3B1 autoantibody as a diagnostic marker in patients with hepatocellular carcinomaJ Transl Med2018161771:CAS:528:DC%2BC1MXhtFKms7vM10.1186/s12967-018-1546-z Toyoda H, Kumada T, Tada T, Sone Y, Kaneoka Y, Maeda A. Tumor markers for hepatocellular carcinoma: simple and significant predictors of outcome in patients with HCC. Liver Cancer. 2015;4(2):126–36. https://doi.org/10.1159/000367735. ZhangNHuZQiangYCirculating miR-130b- and miR-21-based diagnostic markers and therapeutic targets for hepatocellular carcinomaMol Genet Genomic Med20197e10121:CAS:528:DC%2BB3cXkvVehsA%3D%3D KimSUParkJHKimHSLeeJMLeeHGKimHChoiSHBaekSKimBKParkJYKimDYAhnSHLeeJDHanKHSerum Dickkopf-1 as a biomarker for the diagnosis of hepatocellular carcinomaYonsei Med J2015565129613061:CAS:528:DC%2BC28XhtVylsbrM10.3349/ymj.2015.56.5.1296 World Health Organisation (WHO) International agency for research on cancer, The Global Cancer Observatory,Globocan. 2018. https://gco.iarc.fr/today/online-analysis-pie El-DeranyMOPolymorphisms in interleukin 13 signaling and interacting genes predict advanced fibrosis and hepatocellular carcinoma development in non-alcoholic steatohepatitisBiology202097510.3390/biology9040075 OkajimaWKomatsuSIchikawaDMiyamaeMKawaguchiTHirajimaSOhashiTImamuraTKiuchiJAritaTKonishiHShiozakiAMoriumuraRIkomaHOkamotoKTaniguchiHItohYOtsujiECirculating microRNA profiles in plasma: identification of miR-224 as a novel diagnostic biomarker in hepatocellular carcinoma independent of hepatic functionOncotarget2016733538205383610.18632/oncotarget.10781 LiJHanXYuXClinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNAJ Exp Clin Cancer Res20183721310.1186/s13046-018-0893-1 RichNSingalAHepatocellular carcinoma tumour markers: current role and expectationsBest Pract Res Clin Gastroenterol2014288438531:CAS:528:DC%2BC2cXhsFSiur7J10.1016/j.bpg.2014.07.018 WangHGuoDLiJWeiBZhengHIncreased expression of osteopontin indicates poor prognosis in hepatocellular carcinomaInt J Clin Exp Pathol20181112591659221:CAS:528:DC%2BC1MXitlCrs7%2FJ CourtCMHouSWinogradPSegelNHLiQWZhuYSadeghiSFinnRSGanapathyESongMFrenchSWNainiBVShoSKaldasFMBusuttilRWTomlinsonJSTsengHRAgopianVGA novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinomaLiver Transpl201824794696010.1002/lt.25062 Lu Y, Li N, Gao L, et al. Acetylcarnitine is a candidate diagnostic and prognostic biomarker of hepatocellular carcinoma. Cancer Res. 2016;76(10):2912–20. https://doi.org/10.1158/0008-5472.CAN-15-3199. WuMLiuZLiXZhangALiNDynamic changes in serum markers and their utility in the early diagnosis of all stages of hepatitis B-associated hepatocellular carcinomaOnco Targets Ther2020138278401:CAS:528:DC%2BB3cXhtlGit73L10.2147/OTT.S229835 ZhouJWLiYYueLXLuoCLChenYZhangJYAutoantibody response to Sui1 and its tissue-specific expression in hepatocellular carcinomaTumor Biol201637254725531:CAS:528:DC%2BC2MXhsFKktL3K10.1007/s13277-015-4074-y ChenRXuXTaoYExosomes in hepatocellular carcinoma: a new horizonCell Commun Signal201917110.1186/s12964-018-0315-1 485_CR19 H Wang (485_CR16) 2018; 11 J Li (485_CR36) 2018; 37 M Wu (485_CR4) 2020; 13 T Hiroaki (485_CR7) 2019; 11 RM de Oliveira (485_CR24) 2018; 7 N Fujiwara (485_CR22) 2018; 67 K Higai (485_CR20) 2005; 1725 T Sun (485_CR17) 2018; 97 E Åstrom (485_CR21) 2017; 12 CM Court (485_CR37) 2018; 24 W Okajima (485_CR35) 2016; 7 M Lin (485_CR23) 2018; 11 X Li (485_CR40) 2020; 19 S Seino (485_CR11) 2018; 9 R Chen (485_CR39) 2019; 17 A Klein (485_CR26) 2010; 4 S Tang (485_CR29) 2019; 116 European Association for the Study of the Liver (485_CR5) 2018; 69 Y Yoshida (485_CR25) 2018; 35 N Rich (485_CR15) 2014; 28 N Zhang (485_CR38) 2019; 7 MJ Citores (485_CR28) 2019; 11 G Oldenhove (485_CR30) 2018; 25 PP Song (485_CR8) 2016; 22 T Sun (485_CR18) 2018; 11 SJ Park (485_CR12) 2017; 96 L Chen (485_CR41) 2018; 9 JW Zhou (485_CR31) 2016; 37 ES Janf (485_CR14) 2016; 11 L Zhou (485_CR9) 2006; 12 MO El-Derany (485_CR27) 2020; 9 HM Hwang (485_CR32) 2018; 16 485_CR33 485_CR10 485_CR13 T Mocan (485_CR34) 2020; 9 C Kayaalp (485_CR42) 2017; 48 SU Kim (485_CR2) 2015; 56 L Zhang (485_CR3) 2018; 56 C Jiao (485_CR6) 2018; 14 485_CR1 |
| References_xml | – volume: 12 start-page: e0173897 issue: 3 year: 2017 ident: 485_CR21 publication-title: PLoS One doi: 10.1371/journal.pone.0173897 contributor: fullname: E Åstrom – volume: 11 start-page: 8925 year: 2018 ident: 485_CR18 publication-title: Onco Targets Therapy doi: 10.2147/OTT.S186230 contributor: fullname: T Sun – volume: 1725 start-page: 128 year: 2005 ident: 485_CR20 publication-title: Biochim Biophys Acta doi: 10.1016/j.bbagen.2005.03.012 contributor: fullname: K Higai – volume: 69 start-page: 182 year: 2018 ident: 485_CR5 publication-title: J Hepatol doi: 10.1016/j.jhep.2018.03.019 contributor: fullname: European Association for the Study of the Liver – volume: 19 start-page: 1 year: 2020 ident: 485_CR40 publication-title: Mol Cancer doi: 10.1186/s12943-019-1085-0 contributor: fullname: X Li – volume: 9 start-page: 75 year: 2020 ident: 485_CR27 publication-title: Biology doi: 10.3390/biology9040075 contributor: fullname: MO El-Derany – volume: 116 start-page: 49 year: 2019 ident: 485_CR29 publication-title: PNAS contributor: fullname: S Tang – volume: 4 start-page: 372 year: 2010 ident: 485_CR26 publication-title: Proteomics Clin Appl doi: 10.1002/prca.200900151 contributor: fullname: A Klein – volume: 11 start-page: 5916 issue: 12 year: 2018 ident: 485_CR16 publication-title: Int J Clin Exp Pathol contributor: fullname: H Wang – volume: 7 start-page: 53820 issue: 33 year: 2016 ident: 485_CR35 publication-title: Oncotarget doi: 10.18632/oncotarget.10781 contributor: fullname: W Okajima – volume: 11 start-page: 50 issue: 1 year: 2019 ident: 485_CR28 publication-title: World J Hepatol doi: 10.4254/wjh.v11.i1.50 contributor: fullname: MJ Citores – volume: 56 start-page: 1771 year: 2018 ident: 485_CR3 publication-title: Med Biol Eng Comput doi: 10.1007/s11517-018-1811-6 contributor: fullname: L Zhang – volume: 17 start-page: 1 year: 2019 ident: 485_CR39 publication-title: Cell Commun Signal doi: 10.1186/s12964-018-0315-1 contributor: fullname: R Chen – volume: 35 start-page: 467 year: 2018 ident: 485_CR25 publication-title: Glycoconj J doi: 10.1007/s10719-018-9838-3 contributor: fullname: Y Yoshida – volume: 12 start-page: 1175 issue: 8 year: 2006 ident: 485_CR9 publication-title: World J Gastroenterol doi: 10.3748/wjg.v12.i8.1175 contributor: fullname: L Zhou – volume: 11 start-page: e0151069 issue: 3 year: 2016 ident: 485_CR14 publication-title: PLoS One doi: 10.1371/journal.pone.0151069 contributor: fullname: ES Janf – volume: 28 start-page: 843 year: 2014 ident: 485_CR15 publication-title: Best Pract Res Clin Gastroenterol doi: 10.1016/j.bpg.2014.07.018 contributor: fullname: N Rich – volume: 7 start-page: e1012 year: 2019 ident: 485_CR38 publication-title: Mol Genet Genomic Med doi: 10.1002/mgg3.1012 contributor: fullname: N Zhang – volume: 48 start-page: 268 year: 2017 ident: 485_CR42 publication-title: J Gastrointest Cancer doi: 10.1007/s12029-017-9965-2 contributor: fullname: C Kayaalp – volume: 9 start-page: 21844 issue: 31 year: 2018 ident: 485_CR11 publication-title: Oncotarget doi: 10.18632/oncotarget.25074 contributor: fullname: S Seino – volume: 7 start-page: 328 year: 2018 ident: 485_CR24 publication-title: Front Oncol doi: 10.3389/fonc.2017.00328 contributor: fullname: RM de Oliveira – ident: 485_CR13 doi: 10.1159/000367735 – volume: 56 start-page: 1296 issue: 5 year: 2015 ident: 485_CR2 publication-title: Yonsei Med J doi: 10.3349/ymj.2015.56.5.1296 contributor: fullname: SU Kim – volume: 14 start-page: 1239 year: 2018 ident: 485_CR6 publication-title: J Can Res Ther doi: 10.4103/0973-1482.199784 contributor: fullname: C Jiao – volume: 13 start-page: 827 year: 2020 ident: 485_CR4 publication-title: Onco Targets Ther doi: 10.2147/OTT.S229835 contributor: fullname: M Wu – ident: 485_CR10 doi: 10.1038/s41598-019-48043-1 – ident: 485_CR1 – volume: 67 start-page: 1 year: 2018 ident: 485_CR22 publication-title: Gut doi: 10.1136/gutjnl-2017-315193 contributor: fullname: N Fujiwara – volume: 37 start-page: 2547 year: 2016 ident: 485_CR31 publication-title: Tumor Biol doi: 10.1007/s13277-015-4074-y contributor: fullname: JW Zhou – volume: 22 start-page: 262 issue: 1 year: 2016 ident: 485_CR8 publication-title: World J Gastroenterol doi: 10.3748/wjg.v22.i1.262 contributor: fullname: PP Song – volume: 9 start-page: 1541 year: 2020 ident: 485_CR34 publication-title: J Clin Med. doi: 10.3390/jcm9051541 contributor: fullname: T Mocan – volume: 37 start-page: 213 year: 2018 ident: 485_CR36 publication-title: J Exp Clin Cancer Res doi: 10.1186/s13046-018-0893-1 contributor: fullname: J Li – ident: 485_CR19 doi: 10.1158/0008-5472.CAN-15-3199 – volume: 11 start-page: 887 issue: 10 year: 2019 ident: 485_CR7 publication-title: World J Gastrointest Oncol doi: 10.4251/wjgo.v11.i10.887 contributor: fullname: T Hiroaki – volume: 96 start-page: 11 year: 2017 ident: 485_CR12 publication-title: Medicine contributor: fullname: SJ Park – ident: 485_CR33 doi: 10.1038/s41598-019-47365-4 – volume: 25 start-page: 2053 year: 2018 ident: 485_CR30 publication-title: Cell Rep doi: 10.1016/j.celrep.2018.10.091 contributor: fullname: G Oldenhove – volume: 9 start-page: 513 year: 2018 ident: 485_CR41 publication-title: Cell Death Dis doi: 10.1038/s41419-018-0534-9 contributor: fullname: L Chen – volume: 97 start-page: 43 year: 2018 ident: 485_CR17 publication-title: Medicine contributor: fullname: T Sun – volume: 16 start-page: 177 year: 2018 ident: 485_CR32 publication-title: J Transl Med doi: 10.1186/s12967-018-1546-z contributor: fullname: HM Hwang – volume: 11 start-page: 3101 year: 2018 ident: 485_CR23 publication-title: Onco Targets Ther doi: 10.2147/OTT.S163266 contributor: fullname: M Lin – volume: 24 start-page: 946 issue: 7 year: 2018 ident: 485_CR37 publication-title: Liver Transpl doi: 10.1002/lt.25062 contributor: fullname: CM Court |
| SSID | ssj0064511 |
| Score | 2.3151069 |
| SecondaryResourceType | review_article |
| Snippet | Hepatocellular carcinoma (HCC) is a highly malignant disease and early diagnosis rates remain to be unsatisfactory. Owing to this limitation, advances in... |
| SourceID | proquest crossref pubmed springer |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 1122 |
| SubjectTerms | Biomarkers, Tumor - blood Biomarkers, Tumor - genetics Cancer Research Carcinoma, Hepatocellular - blood Carcinoma, Hepatocellular - diagnosis Carcinoma, Hepatocellular - genetics Carcinoma, Hepatocellular - therapy Early Detection of Cancer - methods Gastroenterology Humans Internal Medicine Liquid Biopsy - methods Liver - pathology Liver Neoplasms - blood Liver Neoplasms - diagnosis Liver Neoplasms - genetics Liver Neoplasms - therapy Medicine Medicine & Public Health Neoplasm Recurrence, Local - diagnosis Neoplasm Recurrence, Local - epidemiology Neoplasm Recurrence, Local - prevention & control Neoplasm Staging - methods Oncology Radiotherapy Review Article Risk Assessment - methods Sensitivity and Specificity Treatment Outcome |
| Title | HCC and Tumor Biomarkers: Does One Size Fits All? |
| URI | https://link.springer.com/article/10.1007/s12029-020-00485-x https://www.ncbi.nlm.nih.gov/pubmed/32827068 https://search.proquest.com/docview/2436400842 |
| Volume | 51 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8QwEB50BfHi-7G-iCBetNKkaZJ6kXXdZREfBxW8lbZJYdFtZbsL6q83020VUQS9h2mZmWTe3wDsB8b4uC3VkRHjDrcBMyaaYidRmmuZSpZKnHfu3crrB3XeQZgc7yN1kT0e1xXJ8qH-nHVj2KmB0Q5qne9Yx3HG2h6fN2Cm1bnoXdYPsEDIrbKYzKkjBFPVrMzPVL7ao29O5rcCaWl3ugv_-uNFmK_cTNKa6MUSTJlsGVZamQ2xB6_kgJSNn2VGfRlmr6r6-grQXrtNokyTu_EgH5Kzfj7A9p1hcULOc1OQm8yQ2_6bId3-qCCtp6fTVbjvdu7aPadaquAkHpcjh8YIQC-0cmPrGdAkpowmnMaUS18brXSg3cRNWRwJ42tMEalIBSbmmgapVNxbg0aWZ2YDSJJ4Ig1sxIOocZZqxF2rl7hb3diTSjThsGZt-DzBzgg_UZKROaFlTlgyJ3xpwl7N_dCqONYtoszk4yJk3BMcgf9ZE9YnYvmg59mQUbpCNeGoFkJY3cLil49t_u34FswxlGPZxrINjdFwbHZgutDj3Ur53gEu6M5X |
| link.rule.ids | 315,782,786,27934,27935,41074,42143,48345,48348,49650,49653,52154 |
| linkProvider | Springer Nature |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dixMxEB-0Bb2XO229s96pEcQXXdhk0yR7L0fthy229aEVfAu7mywU2l3ptnD615vZ7l6RE0HfwyTMTJL5_A3A29DaLk5L9WTEuMedw4yBpthLlOFGppKlEvudxws5_6YGQ4TJ4XUvTFntXqcky5f62OzGsFQD3R1Uu67nLMcmop37DWj2JstPo_oFFoi5VWaTOfWEYKpqlvkzld8_pHtW5r0MafnxjM7-78hP4LQyNEnvoBlP4YHNWtDuZc7J3vwg70hZ-lnG1FvwaFZl2NtAx_0-iTJDlvtNviUfV_kGC3i2xTUZ5LYgXzJLFqufloxWu4L01uubZ_B1NFz2x141VsFLAi53Ho0Rgl4Y5cfONqBJTBlNOI0pl11jjTKh8RM_ZXEkbNdgkEhFKrQxNzRMpeLBOTSyPLPPgSRJINLQ-TyIG-eoRtx3monT1a1bqUQH3te81d8P6Bn6iJOMzNGOObpkjr7twJua_dopOWYuoszm-0IzHgiO0P-sAxcHudzRC5zTKH2hOvChFoKu7mHxl81e_Nvy1_B4vJxN9XQy_3wJJwxlWha1XEFjt93bl_CwMPtXlSb-ApwI0j4 |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS-QwEB-8FeRe_PZu_boIci9nsUmzSeqLrPvBnnregQq-hbZJYcFtZbsL6l9vptsqhyKI72FaZqbNfPzmNwD7obUt3JbqyYhxj7uEGQtNsZcow41MJUslzjsPLuXFjer2kCbneYq_RLvXLcnZTAOyNGWTwzuTHr4MvjGEbWDqgy7Y8lwUOc8RW9iA-XbvdHBe_40F8m-VnWVOPSGYqgZn3pby_-X0KuJ81S0tL6H-0udffxkWqwCUtGceswJzNluFtXbmku_RA_lJSkhoWWtfhYU_Ved9Deig0yFRZsjVdJSPyckwHyGwZ1wckW5uC_I3s-Ry-GhJfzgpSPv29ngdrvu9q87Aq9YteEnA5cSjMVLTC6P82MUMNIkpowmnMeWyZaxRJjR-4qcsjoRtGSweqUiFNuaGhqlUPNiARpZn9juQJAlEGrpcCPnknNSI-85jceu6dSeVaMKvWs_6bsaqoV_4k1E52ilHl8rR903Yq02hnfNjRyPKbD4tNOOB4LgSgDXh28xGz_ICl0xKX6gmHNQG0dX3WbzzsM2PHf8BC_-6fX3---JsC74yNGmJddmGxmQ8tTvwpTDT3copnwDXmtsK |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=HCC+and+Tumor+Biomarkers%3A+Does+One+Size+Fits+All%3F&rft.jtitle=Journal+of+gastrointestinal+cancer&rft.au=Ozgor%2C+Dincer&rft.au=Otan%2C+Emrah&rft.date=2020-12-01&rft.pub=Springer+US&rft.issn=1941-6628&rft.eissn=1941-6636&rft.volume=51&rft.issue=4&rft.spage=1122&rft.epage=1126&rft_id=info:doi/10.1007%2Fs12029-020-00485-x&rft.externalDocID=10_1007_s12029_020_00485_x |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1941-6628&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1941-6628&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1941-6628&client=summon |